Uncategorised - European Medical Journal

Predisposition, Clinical Characteristics and Management of Immune Checkpoint Inhibitor-Induced Nephritis

Immune checkpoint inhibitors (ICI) use can lead to an array of immune-related adverse events (irAE). Nephritis is considered to be…

Advances in Treatment for Oestrogen Receptor-Positive Breast Cancer

THIS YEAR the European Society for Medical Oncology (ESMO) Congress was hosted in Barcelona, Spain from 13th–17th September. Among the…

Cancer Vaccines

An insightful infographic summarising the latest in cancer vaccines research. Information provided summarises the prevalence of certain…

Patient-Centred Therapies for mNSCLC

The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a result of…

ESMO 2024 Abstract Highlights

The following abstracts showcase the top cutting-edge research presented at the European Society for Medical Oncology (ESMO) Congress 2024…

Immunotherapy in Endometrial Cancer: What Should We Know?

IMMUNOTHERAPY with chemotherapy is emerging as a new standard first-line treatment in advanced endometrial cancer (EC). In an insightful…

Synergy of Tumour and Liquid Biopsy

The symposium took place during the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, with the goal of…

Therapeutic Advances in Gastrointestinal Cancers: Immuno-oncology and Beyond

At the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, the latest advancements in immunotherapy for…

Platinum Resistance in Ovarian Cancer

Approximately 80% of females with ovarian cancer are diagnosed with advanced disease (International Federation of Gynecology and…

From Podium into Practice: Working Together to Revolutionise Cancer Care in the Real World

Cancer is on course to be the leading cause of death in the EU by 2035. Europe’s population is ageing rapidly, and obesity rates continue…